ERCC1 induction after oxaliplatin exposure may depend on KRAS mutational status in colorectal cancer patient: preliminary data from liquid biopsy
- Resource Type
- Source
- Journal of Clinical Oncology. 33:11033-11033
- Subject
Oncology Cancer Research medicine.medical_specialty business.industry Colorectal cancer medicine.disease_cause medicine.disease humanities digestive system diseases Oxaliplatin Internal medicine medicine Mutational status KRAS ERCC1 Liquid biopsy business neoplasms medicine.drug - Language
- ISSN
- 1527-7755
0732-183X